Interní Med. 2014; 16(3): 106-109

Recent findings in therapy of oral antidiabetic drugs

MUDr.Alena Adamíková, Ph.D., prof.MUDr.Jaroslav Rybka, DrSc.

Diabetologické centrum KNTB, a.s., Zlín

The therapy of type 2 diabetic patients includes education directed at a change of life style, assessment of microvascular and macrovascular

complications, normalization of glycaemia and minimization of cardiovascular and other risk factors. A majority of diabetic patients

requires continual treatment increasing insulin secretion and sensitivity and reducing saccharide absorption. Initial monotherapy fails

annually in 5–10 % patients. According to an analysis of UKPDS 50 % of patients require a second oral antidiabetic drug after three

years of therapy. Entirely new therapeutic possibilities are provided by DPP-4 inhibitors and GLP-1 receptor agonists and also gliflozins.

New properties, especially in the sphere of prevention of oncological disease, are ascribed to metformin therapy. A further possibility

of therapy is the combination of oral antidiabetic drugs and also GLP-1 RA with basal insulin. Type 2 diabetes mellitus is a progressive

disease and 75 % of patients need combined therapy to achieve the required aims of compensation.

Keywords: type 2 diabetes mellitus, oral antidiabetic drugs, DPP-4 inhibitors, gliflozins

Published: May 26, 2014  Show citation